Biden’s most ambitious health policy: a public option plan

https://www.healthcaredive.com/news/bidens-most-ambitious-health-policy-a-public-option-plan/593342/

“It could fundamentally change how healthcare is priced in the U.S.,” said Cynthia Cox, vice president of the Kaiser Family Foundation.

President-elect Joe Biden will seek to bolster the Affordable Care Act after his predecessor chipped away at the signature legislation, but he also has grander legislative priorities of his own for the health sector.

His most ambitious plan is to create a so-called public option plan, available to all Americans to purchase even if they already have coverage through their employers. It holds the potential to alter how millions get healthcare and put pressure on prices, experts told Healthcare Dive.

“It could fundamentally change how healthcare is priced in the U.S.,” Cynthia Cox, vice president of the Kaiser Family Foundation, told Healthcare Dive.

Still, even with control of Congress and the White House, the plan may take a backseat as the pandemic continues to sicken and kill a record number of people. And while the idea has drawn more support among Democrats in recent years, powerful interests like private insurers and providers will push back against the proposal, while some progressives have their eye on the more ambitious Medicare for All.

A public plan for all

Simply put, a public option plan would give consumers a government-run choice for insurance, a market that can be tightly consolidated, leaving consumers with few carriers to choose from, especially in certain regions of the country.

“If your insurance company isn’t doing right by you, you should have another, better choice,” Biden has touted via his website.

Biden’s proposal allows anyone to buy a public option plan, even those now with employer plans. It is not limited to those only those on the exchanges, or consumers without employer plans.

Biden has said a public option plan will lower prices for patients because the government would be negotiating lower prices with healthcare providers. That theory relies on providers accepting these lower rates and electing to be in-network with the public plan.

The public option plan would reimburse providers less than typical commercial plans, which tend to pay the highest rates to providers for services compared to other government programs such as Medicaid and Medicare.

Ultimately, it is a more direct way to regulate healthcare prices in the U.S., Cox said.

As such, it will face fierce opposition from providers who typically treasure commercial insurance over other government plans as it tends to generate less revenue for hospitals and payers who see the option as competition.

A public option plan was included in early drafts during the construction of the ACA, though at the time it was limited to those without employer coverage. The idea gained support because policymakers were unsure how many private plans would sell plans on exchange. Plus, at the time, the idea was that it would offer premium pricing pressure and more choices in areas that potentially did not attract any on-exchange carriers. 

In 2013, the Congressional Budget Office scrutinized the impact of adding a public plan to the exchanges. At the time, CBO’s estimates expected premiums to be lower than private plans by 7% and 8% on average. And CBO estimates showed it would reduce the federal deficit in a few ways, mainly through a decrease in subsidies as consumers opted for the public plan.

In the end, though, the idea was nixed to gain backing from moderate Democrats as Republicans villified it as a government takeover of healthcare.

Not bold enough for far-left Democrats

While the public option was called too far left at the time of the ACA, it now may not be progressive enough for those in the liberal wing of the party, as ideas like Medicare for All have become more mainstream.

The shock of the COVID-19 pandemic may hasten calls for a bigger revamp, having laid bare the deep inequities in the nation’s healthcare system. Both death and infection rates are higher for people of color compared with their White counterparts.

At the same time, millions have likely lost insurance coverage as the economic upheaval caused by the pandemic resulted in historic job losses. Many Americans receive health coverage through work.

Earlier periods of upheaval paved the way for bold social programs such as those that followed the Great Depression via President Franklin D. Roosevelt’s New Deal.

Prior to the pandemic, a public option was seen as more palatable for some than a “Medicare for All” option, a favored policy among the more progressive wing of the Democratic party. It was a heavily debated topic during the Democratic primary, during which Biden cautioned that such a plan would mean eliminating the ACA, a signature policy he helped enact as vice president.

A public option plan, while an ambitious measure, is not as industry-altering as Medicare for All, which would force Americans onto a single system and eliminate the private insurance market. A wing of the party’s progressive group continues to advocate for Medicare for All.

The Democrats currently have a 10-vote margin in the House, and an even slimmer margin in the Senate with Vice President-elect Kamala Harris serving as the tiebreaker.

Some had suggested those farther left in the party should withhold their votes for Nancy Pelosi as speaker of the House in exchange for securing a floor vote on Medicare for All. Pelosi ultimately retained her speakership position.

But Rep. Alexandria Ocasio-Cortez, D-N.Y., batted down such ideas as premature on Twitter due to the lack of Democratic votes to pull off such a move successfully.  

“So you issue threats, hold your vote, and lose. Then what?” Ocasio-Cortez tweeted on Dec. 11.

Reconciliation

Even with Democrats in control of Congress and the White House, don’t expect any sweeping healthcare legislative changes like Medicare for All, experts say.

The margins are so slim in the Senate it leaves one avenue to pass legislation: through so-called budget reconciliation. That avenue comes with complicated rules, generally limiting the kind of bills that can be passed to those with an impact on revenue, spending or deficits.

Given that hurdle alone, industry analysts don’t expect a public plan to pass through Congress, instead pointing to more incremental changes, which eases market fears of broad changes.

Plus, the pandemic will be absorbing most of the attention as the 46th president tries to stamp out the pandemic.

“Not to be overly simplistic, but I don’t think healthcare is on the front page of priorities,” David Windley, an analyst with Jefferies, said, pointing to Biden’s transition website, which does not call out other healthcare policy goals aside from tackling the pandemic.

It sets the table for a unique first term, Andy Slavitt, former CMS acting administrator under President Barack Obama, said. Slavitt will serve as a senior adviser to Biden’s COVID-19 response.

“For the first time in a long time, healthcare will not be a big first-term agenda item for the Congress,” Slavitt said during a healthcare conference last week. He expects Biden to focus on building back the ACA through administrative action and rule making as opposed to legislative battles in Congress.

“I don’t think Biden is looking to pick big divisive fights to the extent that healthcare looks like a big divisive fight. It doesn’t strike me that that’s where he wants to be,” Slavitt said.

Biden ramps up vaccine distribution to 200 million doses by the end of summer

https://www.healthcarefinancenews.com/news/biden-ramps-vaccine-distribution-200-million-doses-end-summer

Biden administration to buy 200 million more doses of Covid vaccine -  POLITICO

The death toll from the pandemic is projected to climb to 500,000 by the end of  February.

President Joe Biden yesterday announced he is ramping up COVID-19 vaccine distribution to have 200 million doses delivered by the end of the summer.

This is an additional 100 million doses Biden set as his goal for his first 100 days in office.

In remarks yesterday, Biden directed COVID-19 Response Coordinator Jeff Zeints to work with the Department of Health and Human Services to increase the nation’s total supply. 

“And we believe that we’ll soon be able to confirm the purchase of an additional 100 million doses for each of the two FDA-authorized vaccines: Pfizer and Moderna,” Biden said. “That’s 100 million more doses of Pfizer and 100 million more doses of Moderna — 200 million more doses than the federal government had previously secured. Not in hand yet, but ordered. We expect these additional 200 million doses to be delivered this summer.”

After review of the current vaccine supply from manufacturing plants, the federal government believes it can increase overall weekly vaccination distribution to states, tribes, and territories from 8.6 million doses to a minimum of 10 million doses, starting next week.  

But the pandemic is expected to get worse before it gets better, Biden said, with experts predicting the death toll as likely to top 500,000 by the end of  February.

But the brutal truth is: It’s going to take months before we can get the majority of Americans vaccinated. Months. In the next few months, masks — not vaccines — are the best defense against COVID-19,” he said.

WHY THIS MATTERS

The increases in the total vaccine order in the United States from 400 million ordered to 600 million doses will be enough vaccine to fully vaccinate 300 Americans by the end of the summer or the beginning of fall, Biden said.  

“It’ll be enough to fully vaccinate 300 [million] Americans to beat this pandemic — 300 million Americans,” he said. “And this is an aggregate plan that doesn’t leave anything on the table or anything to chance, as we’ve seen happen in the past year.”

Biden’s team said they found the vaccine program to be in worse shape than they thought it would be and that they were starting from scratch.

“But it’s also no secret that we have recently discovered, in the final days of the transition — and it wasn’t until the final days we got the kind of cooperation we needed — that once we arrived, the vaccine program is in worse shape than we anticipated or expected,” Biden said. 

Governors have been guessing at what they’ll receive for vaccine shipments, the president said.

The federal  government is working with the private industry to ramp up production of vaccine and protective equipment such as syringes, needles, gloves, swabs and masks. The team has already identified suppliers and is working with them to move the plan forward.

Also, the Federal Emergency Management Agency is being directed to to stand up the first federally-supported community vaccination centers and to make  vaccines available to thousands of local pharmacies beginning in early February.

THE LARGER TREND

Last week, Biden signed a declaration to begin reimbursing states 100% for the use of their National Guard to help the COVID-19 relief effort, both in getting sites set up and in using some of their personnel to administer the vaccines. 

Biden has also said he wants to expand testing, which will help reopen schools and businesses.

He has formalized the Health Equity Task Force to ensure that the most vulnerable populations have access to vaccines. 

He is also pushing for a $1.9 trillion relief package.

My Parents Will Be Vaccinated Long Before Me. Can They Come Visit?

Can I Visit People Who Are Vaccinated During COVID-19? | Time

Welcome to COVID Questions, TIME’s advice column. We’re trying to make living through the pandemic a little easier, with expert-backed answers to your toughest coronavirus-related dilemmas. While we can’t and don’t offer medical advice—those questions should go to your doctor—we hope this column will help you sort through this stressful and confusing time. Got a question? Write to us at covidquestions@time.com.

Today, E.B. in New York asks:

My parents and in-laws will hopefully be vaccinated soon. My husband and toddler and I don’t expect to be vaccinated for quite some time. How should we think about whether it’s safe to spend time together in a mixed-vaccinated group? Could they get on a plane and fly to visit with us unmasked and indoors? Or is there enough risk that we should wait until we are all vaccinated (which may be a very long time especially with children in the mix)? Or split the difference and take some precautions?

To state the obvious, we are in a strange limbo state right now. The vaccines we’ve eagerly awaited for almost a year are here, and yet…nothing about our daily lives has really changed. Unfortunately, that’s going to be the case for a bit longer.

“The end is in sight,” says Dr. Colleen Kelley, a vaccine researcher and associate professor of infectious diseases at the Emory University School of Medicine in Georgia. “I just don’t know that it’s right now.”

Your loved ones getting vaccinated is unequivocally a step forward, Kelley says. It would certainly be safer to visit with your parents or in-laws after they’ve gotten both vaccine doses, but the safest plan is to wait until you and your husband are also vaccinated, she says.

The two coronavirus vaccines currently authorized for use in the U.S.—those made by Pfizer-BioNTech and Moderna—are both extremely effective at preventing people from getting sick with COVID-19. That’s a huge benefit on its own, especially for people at high risk of severe illness, such as elderly adults and people with underlying medical conditions.

But the outstanding question is whether COVID-19 vaccines also stop people from getting asymptomatically infected with the virusEarly evidence suggests both shots offer at least some protection against asymptomatic infection, and many experts are optimistic about their chances of stopping transmission, but the data are still coming together.

If the shots turn out not to stop asymptomatic infections entirely, even your vaccinated parents could feasibly get your family sick if they picked something up while traveling to see you. Or, if you happened to be exposed to the virus, your parents could potentially carry it and pass it to others. And, while the authorized COVID-19 vaccines are very effective, there is always a tiny chance of them failing, leaving your parents at risk of illness.

These are all worst-case scenarios, of course. But given the uncertainty and the extent to which COVID-19 is still spreading in the U.S., Kelley says you should wait a little while longer to visit with your parents and in-laws. If that’s not possible, you should take the same precautions you’ve been hearing about for a year: quarantining beforehand, and ideally staying outdoors and masked when possible.

Here’s the good news, though. Once you and your husband are fully vaccinated (along with more of the general population), Kelley says you can feel much better about spending time with other vaccinated people indoors and unmasked—even if your toddler isn’t yet vaccinated.

As you suggest, it may be a while before kids younger than 16 are eligible for COVID-19 vaccination, since pharmaceutical companies haven’t yet finished testing their shots on younger children. But “if the toddler is the only one who’s not vaccinated, I would say that’s a pretty darn safe scenario,” Kelley says.

Luckily, young kids rarely get seriously ill with COVID-19, so once all the adults in the room are fully protected, Kelley says you can feel pretty comfortable with your parents or in-laws coming for a visit.

“We’re not going to get to a zero-risk situation,” Kelley says, “but we are going to get to places that are safer and safer.”

Report American Billionaires have added more than 1 trillion in wealth during pandemic

Report: American Billionaires Have Added More Than $1 Trillion In Wealth During Pandemic

America’s billionaires have added a staggering $1.1 trillion to their collective wealth since the pandemic began. Their combined fortunes now sit at $4.1 trillion — $1.7 trillion more than the amount of wealth held by the bottom half of Americans.

Meanwhile, the country’s poverty rate increased by 2.4 percentage points in the latter half of 2020 — the largest increase in poverty since the 1960s. And to think that Senate Republicans are decrying a $1.9 trillion COVID relief bill as too expensive.

Please. America’s billionaires alone could finance most of that bill, just with the increase in their wealth over the last 10 months. An emergency wealth tax that used their $1.1 trillion windfall to pay for the COVID survival plan would put these billionaires back to where they were 10 months ago (still very comfortable, to say the least) while helping the rest of America survive.

This is the sort of trickle-down economics that could actually work. What do you think?

Michael Dowling: No one said it would be easy

Five suggestions for technology companies, venture capitalists | Northwell  Health

Hardly one month into 2021, the pressing priorities facing healthcare leaders are abundantly clear. 

First, we will be living in a world preoccupied by COVID-19 and vaccination for many months to come. Remember: this is a marathon, not a sprint. And the stark reality is that the vaccination rollout will continue well into the summer, if not longer, while at the same time we continue to care for hundreds of thousands of Americans sickened by the virus. Despite the challenges we face now and in the coming months in treating the disease and vaccinating a U.S. population of 330 million, none of us should doubt that we will prevail. Despite the federal government’s missteps over the past year in managing and responding to this unprecedented public health crisis, historians will recognize the critical role of the nation’s healthcare community in enabling us to conquer this once-in-a-generation pandemic.

While there has been an overwhelming public demand for the vaccine during the past couple of weeks, there remains some skepticism within the communities we serve, including some of the most-vulnerable populations, so healthcare leaders will find themselves spending time and energy communicating the safety and efficacy of vaccines to those who may be hesitant. This is a good thing. It is our responsibility to share facts, further public education and influence public policy. COVID-19 has enhanced public trust in healthcare professionals, and we can maintain that trust if we keep our focus on the right things — namely, how we improve the health of our communities.

And as healthcare leaders diligently balance this work, we also have a great opportunity to reimagine what our hospitals and health systems can be as we emerge from the most trying year of our professional lifetimes. How do you want your hospital or system organized? What kind of structural changes are needed to achieve the desired results? What do you really want to focus on? Amid the pressing priorities and urgent decision-making needed to survive, it is easy to overlook the great reimagination period in front of us. The key is to forget what we were like before COVID-19 and reflect upon what we want to be after.

These changes won’t occur overnight. We’ll need patience, but here are my thoughts on five key questions we need to answer to get the right results.

1. How do you enhance productivity and become more efficient? Throughout 2021, most systems will be in recovery mode from COVID’s financial bruises. Hospitals saw double-digit declines in inpatient and outpatient volumes in 2020, and total losses for hospitals and health systems nationwide were estimated to total at least $323 billion. While federal relief offset some of our losses, most of us still took a major financial hit. As we move forward, we must reorganize to operate as efficiently as possible. Does reorganization sound daunting? If so, remember the amount of reorganization we mustered to work effectively in the early days of the pandemic. When faced with no alternative, healthcare moved heaven and earth to fulfill its mission. Crises bring with them great clarity. It’s up to leaders to keep that clarity as this tragic, exhausting and frustrating crisis gradually fades.

2. How do you accelerate digital care? COVID-19 changed our relationship with technology, personally and professionally. Look at what we accomplished and how connected we remain. We were reminded of how high-quality healthcare can go unhindered by distance, commutes and travel constraints with the right technology and telehealth programs in place. Health system leaders must decide how much of their business can be accommodated through virtual care so their organizations can best offer convenience while increasing access. Oftentimes, these conversations don’t get far before confronting doubts about reimbursement. Remember, policy change must happen before reimbursement catches up. If you wait for reimbursement before implementing progressive telehealth initiatives, you’ll fall behind. 

3. How will your organization confront healthcare inequities? In 2020, I pledged that Northwell would redouble its efforts and remain a leader in diversity and inclusion. I am taking this commitment further this year and, with the strength of our diverse workforce, will address healthcare inequities in our surrounding communities head-on. This requires new partnerships, operational changes and renewed commitments from our workforce. We need to look upstream and strengthen our reach into communities that have disparate access to healthcare, education and resources. We must push harder to transcend language barriers, and we need our physicians and medical professionals of color reinforcing key healthcare messages to the diverse communities we serve. COVID-19’s devastating effect on communities of color laid bare long-standing healthcare inequalities. They are no longer an ugly backdrop of American healthcare, but the central plot point that we can change. If more equitable healthcare is not a top priority, you may want to reconsider your mission. We need leaders whose vision, commitment and courage match this moment and the unmistakable challenge in front of us. 

4. How will you accommodate the growing portion of your workforce that will be remote? Ten to 15 percent of Northwell’s workforce will continue to work remotely this year. In the past, some managers may have correlated remote work and teams with a decline in productivity. The past year defied that assumption. Leaders now face decisions about what groups can function remotely, what groups must return on-site, and how those who continue to work from afar are overseen and managed. These decisions will affect your organizations’ culture, communications, real estate strategy and more. 

5. How do you vigorously hold onto your cultural values amid all of this change? This will remain a test through 2021 and beyond. Culture is the personality of your organization. Like many health systems and hospitals, much of Northwell’s culture of connectedness, awareness, respect and empathy was built through face-to-face interaction and relationships where we continually reinforced the organization’s mission, vision and values. With so many employees now working remotely, how can we continue to bring out the best in all of our people? We will work to answer that question every day. The work you put in to restore, strengthen and revitalize your culture this year will go a long way toward cementing how your employees, patients and community come to see your organization for years to come. Don’t underestimate the power of these seemingly simple decisions.

While we’ve been through hell and back over the past year, I’m convinced that the healthcare community can continue to strengthen the public trust and admiration we’ve built during this pandemic. However, as we slowly round the corner on COVID-19, our future success will hinge on what we as healthcare organizations do now to confront the questions above and others head-on. It won’t be quick or easy and progress will be a jagged line. Let’s resist the temptation to return to what healthcare was and instead work toward building what healthcare can be. After the crisis of a lifetime, here’s our opportunity of a lifetime. We can all be part of it. 

3 healthcare executive actions expected from Biden this week

Biden sets agenda on Day One with executive actions | kare11.com

President Joe Biden is expected to sign executive actions this week related to immigration, healthcare and climate, according to a memo obtained by The Hill.

The executive actions would follow 10 he signed Jan. 21 to combat COVID-19 spread.

Here are the three healthcare executive actions to expect Jan. 28, according to The Hill

1. President Biden is set to rescind a policy banning foreign aid for abortion, known as the Mexico City policy. It prohibits the use of U.S. funds for foreign and national health organizations that perform or actively promote abortion, according to NBC News. The policy was announced by former President Ronald Reagan in 1984. According to The Hill, it has been rescinded by Democratic presidents and reinstated by Republican presidents, including former President Donald Trump, since then.

2. President Biden will also call for a review of the Title X family planning program, according to a memo obtained by The Hill. The federal program provides family planning and related preventive health services for low-income or uninsured people and others. In 2019, the Trump administration issued a final rule prohibiting providers that receive federal family planning money under the program from providing or promoting abortions. NBC News reported that the Biden administration is expected to back off this rule and “restore federal funding for Planned Parenthood,” which left the program in 2019.

3. President Biden plans to sign an executive action on Medicaid and initiate an open enrollment period under the ACA, according to a memo obtained by The Hill. The annual open enrollment period for 2021 closed in December. However, President Biden could initiate a special enrollment period. 

Colchicine for Early COVID-19? Trial May Support Oral Therapy at Home

But some find science-by-press-release troubling.

Anti-inflammatory oral drug colchicine improved COVID-19 outcomes for patients with relatively mild cases, according to certain topline results from the COLCORONA trial announced in a brief press release.

Overall, the drug used for gout and rheumatic diseases reduced risk of death or hospitalizations by 21% versus placebo, which “approached statistical significance.”

However, there was a significant effect among the 4,159 of 4,488 patients who had their diagnosis of COVID-19 confirmed by a positive PCR test:

  • 25% fewer hospitalizations
  • 50% less need for mechanical ventilation
  • 44% fewer deaths

If full data confirm the topline claims — the press release offered no other details, and did not mention plans for publication or conference presentation — colchicine would become the first oral drug proven to benefit non-hospitalized patients with COVID-19.

“Our research shows the efficacy of colchicine treatment in preventing the ‘cytokine storm’ phenomenon and reducing the complications associated with COVID-19,” principal investigator Jean-Claude Tardif, MD, of the Montreal Heart Institute, said in the press release. He predicted its use “could have a significant impact on public health and potentially prevent COVID-19 complications for millions of patients.”

Currently, the “tiny list of outpatient therapies that work” for COVID-19 includes convalescent plasma and monoclonal antibodies, which “are logistically challenging (require infusions, must be started very early after symptom onset),” tweeted Ilan Schwartz, MD, PhD, an infectious diseases researcher at the University of Alberta in Edmonton.

The COLCORONA findings were “very encouraging,” tweeted Martin Landray, MB ChB, PhD, of the Big Data Institute at the University of Oxford in England. His group’s RECOVERY trial has already randomized more than 6,500 hospitalized patients to colchicine versus usual care as one of the arms of the platform trial, though he did not offer any findings from that study.

“Different stage of disease so remains an important question,” he tweeted. “Maybe old drugs can learn new tricks!” Landray added, pointing to dexamethasone.

A small open-label, randomized trial from Greece had also shown less clinical status deterioration in hospitalized patients on colchicine.

“I think this is an exciting time. Many groups have been pursuing lots of different questions related to COVID and its complications,” commented Richard Kovacs, MD, immediate past-president of the American College of Cardiology. “We’re now beginning to see the fruit of those studies.”

The COLCORONA announcement came late Friday, following closely on the heels of the topline results from the ACTIVE-4a, REMAP-CAP, and ATTACC trials showing a significant morbidity and mortality advantage to therapeutic-dose anticoagulation in non-ICU patients in the hospital for COVID-19.

COLCORONA was conducted remotely, without in-person contact, with participants across Canada, the U.S., Europe, South America, and South Africa. It randomized participants double-blind to colchicine 0.5 mg or a matching placebo twice daily for the first 3 days and then once daily for the last 27 days.

Participants were ages 40 and older, not hospitalized at the time of enrollment, and had at least one risk factor for COVID-19 complications: age 70-plus, obesity, diabetes, uncontrolled hypertension, known asthma or chronic obstructive pulmonary disease, known heart failure, known coronary disease, fever of ≥38.4°C (101.12°F) within the last 48 hours, dyspnea at presentation, or certain blood cell abnormalities.

It had been planned as a 6,000-patient trial, but whether it was stopped for efficacy at a preplanned interim analysis or for some other reason was not spelled out in the press release. Whether the PCR-positive subgroup was preplanned also wasn’t clear. Key details such as confidence intervals, adverse effects, and subgroup results were omitted as well.

While a full manuscript is reportedly underway, “we don’t know enough to bring this into practice yet,” argued Kovacs.

The centuries-old drug has long been used for gout and arthritis and more recently for pericarditis along with showing promise in cardiovascular secondary prevention.

However, the drug isn’t as inexpensive in the U.S. as in Canada, Kovacs noted.

Some physicians also warned about the potential for misuse of the findings and attendant risks.

Dhruv Nayyar, MD, of the University of Toronto, tweeted that he has already had “patients inquiring why we are not starting colchicine for them. Science by press release puts us in a difficult position while providing care. I just want to see the data.”

Angela Rasmussen, MD, a virologist with the Georgetown Center for Global Health Science and Security’s Viral Emergence Research Initiative in Washington, agreed, tweeting: “When HCQ [hydroxychloroquine] was promoted without solid data, there was at least one death from an overdose. We don’t need people self-medicating with colchicine.”

As was the case with hydroxychloroquine before the papers proved little efficacy in COVID-19, Kovacs told MedPage Today: “We always get concerned when these drugs are repurposed that we might see an unintended run on the drug and lessen the supply.”

Citing the well-known diarrheal side effect of colchicine, infectious diseases specialist Edsel Salvana, MD, of the University of Pittsburgh and University of the Philippines in Manila, tweeted a plea for use only in the trial-proven patient population with confirmed COVID-19 — not prophylaxis.

The dose used was on par with that used in cardiovascular prevention and other indications, so the diarrhea incidence would probably follow the roughly 10% rate seen in the COLCOT trial, Kovacs suggested.

In the clinic, too, there are some cautions. As Elin Roddy, MD, a respiratory physician at Shrewsbury and Telford Hospital NHS Trust in England, tweeted: “Lots of drug interactions with colchicine potentially — statins, macrolides, diltiazem — we have literally been running up to the ward to cross off clarithromycin if RECOVERY randomises to colchicine.”

Drug Prices: We’ve Seen This Movie Before

As happened with cars in the 1960s, price competition among brand-name drugs is hard to find.

Before 1973, when the Arab oil embargo upended the U.S. auto industry, Americans witnessed an annual ritual by carmakers. In the late summer, the Big Three — Ford, Chrysler, and General Motors — would release sticker prices for their products, always showing increases, of course.

Almost always, the increases from each company for similar models were nearly identical. If one company’s was out of line — substantially bigger or smaller than its erstwhile competitors’ — it quickly made an adjustment. Explicit collusion to fix prices was never proven, but the effect for consumers was the same.

Now, researchers report that something very similar seems to be occurring for big-market brand-name drugs, including anti-diabetic medications and blood thinners.

Average wholesale prices for products in five classes — direct-acting oral anticoagulants (DOACs), P2Y12 inhibitors, glucagon-like peptide-1 (GLP-1) agonists, dipeptidyl dipeptidase-4 (DPP-4) inhibitors, and sodium-glucose transport protein-2 (SGLT-2) inhibitors — increased in “lock-step” each year from 2015 to 2020, according to Joseph Ross, MD, of Yale University in New Haven, Connecticut, and colleagues writing in JAMA Network Open.

These increases ranged from annual averages of 6.6% for DDP4 inhibitors to 13.5% for P2Y12 inhibitors — far outpacing not only inflation in general, but even the 2.1% average for all prescription drugs.

Within each class, Kendall τb correlation coefficients for average wholesale prices were as follows:

  • DOACs: 0.98
  • SGLT-2 inhibitors: 0.98
  • DPP-4 inhibitors: 0.96
  • GLP-1 agonists: 0.92
  • P2Y12 inhibitors: 0.75

“These results suggest there was little price competition among the sponsors of these products,” Ross and colleagues wrote.

Although the analysis came with significant limitations — it didn’t account for rebates or other discounts, for example — the researchers said some patients must suffer from these increases.

“Rebates, list prices, and net prices have been growing for brand-name medications, and rebate growth has been shown to positively correlate with list price growth, thereby impacting costs faced by patients paying a percentage of (or the full) list price, the group noted. “Therefore, the lock-step price increases of brand-name medications, without evidence of price competition, raise concerns and would be expected to adversely affect patient adherence to medications and thus clinical outcomes.”

For the car buyers, the solution to lock-step price increases was imposed from outside: soaring gas prices in the mid-1970s prompted demand for vehicles with better fuel economy than domestic makers were prepared to sell. That opened the market to Japanese cars that not only got better mileage, but were also more reliable and (in many cases) cheaper than Big Three products. Thus ended Detroit’s ability to set prices.

How to rein in Big Pharma is less clear. For their part, Ross and colleagues suggested policies to limit such lock-step price hikes, shortened patent exclusivity periods, and faster introduction of generic equivalents.